In the third part of the Myeloma Series, The Fellow on Call hosts break down the progression of
monoclonal gammopathy of undetermined significance and smoldering myeloma to multiple myeloma (MM). In the episode, they discuss risk stratification and treatment response monitoring in patients, including the need for both FISH and karyotype testing when risk stratifying a patient with MM and why minimal residual disease testing is important.